항생제 내성 시장 : 약제 클래스별, 질환별, 유통 채널별, 지역별

Antibiotic Resistance Market is estimated to be valued at USD 9.34 Bn in 2026 and is expected to reach USD 13.77 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.

The global antibiotic resistance market has been witnessing significant growth in recent years. Antibiotics are medicines used to prevent and treat bacterial infections. They either kill bacteria or stop them from multiplying. Some of the most commonly used antibiotics include penicillin, amoxicillin, cephalosporins etc. However, over the past few decades, antibiotic resistance has been emerging as a major public health threat globally. When bacteria become antibiotic resistant, the medicines used to treat the infections they cause become ineffective. This leads to longer illness and increased death rates. The rising prevalence of bacterial strains that are resistant to various antibiotic classes is primarily attributable to misuse and overuse of antibiotics. Other factors that drive antibiotic resistance include the lack of development of new antibiotics, lack of sanitation and hygiene in many parts of the world, increased international travels, etc. If not addressed properly, antibiotic resistance could lead to serious health issues and affect patient outcomes.

Market Dynamics

The global antibiotic resistance market growth is driven by various factors such as increasing prevalence of antibiotic-resistant bacterial infections, lack of new antibiotic development, misuse and overuse of existing antibiotics, limited infection control in many developing regions, etc. However, the development of alternative treatment options and stringent regulations regarding antibiotic usage could restrain the market growth. The market provides opportunities for companies focusing on the development of novel antibiotics with new mechanisms of action. Key players are also exploring alternative therapeutic approaches like phage therapy, vaccines, monoclonal antibodies etc. to counter antibiotic resistance. Partnerships between industry and academia hold promise to address this looming healthcare crisis.

Key Features of the Study

• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global antibiotic resistance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceutials, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, NEMESIS BIOSCIENCE LTD.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global antibiotic resistance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibiotic resistance market.

Market Segmentation

• Global Antibiotic Resistance Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Cephalosporins
• Others (Combination therapies, etc.)
• Global Antibiotic Resistance Market, By Disease (Revenue, USD Bn, 2021 - 2033)
• cUTI (Complicated Urinary Tract Infections)
• CDI (Clostridioides difficile Infection)
• ABSSSI (Acute bacterial skin and skin structure infections)
• HABP (Hospital-acquired bacterial pneumonia)
• CABP (Community-acquired pneumonia)
• cIAI (Complicated intra-abdominal infection)
• Others (BSI (Bloodstream infection), etc.)
• Global Antibiotic Resistance Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Antibiotic Resistance Market, By Region (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Top Companies in the Global Antibiotic Resistance Market
• Melinta Therapeutics
• Merck & Co., Inc.
• Allergan
• Pfizer Inc.
• Tetraphase Pharmaceutical, Inc.
• Theravance Biopharma
• WOCKHARDT
• Entasis Threapeutics
• Paratek Pharmaceutials, Inc.
• Seres Therapeutics
• Achaogen Inc.
• Basilea Pharmaceutical Ltd.
• Nabriva Threapeutics plc
• NEMESIS BIOSCIENCE LTD.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Disease
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising prevalence of infectious diseases
  • Advancement in antibiotic resistance diagnosis
  • Growing number of R&D activities
• Key Highlights
• Guidelines for the Temporary Staffing Agency & the Host Employer
• Market Trends
• PEST Analysis
• Investments and Fundings
• Mergers, Acquisitions, and Collaborations
• Key Services Offered
• Identification of Top Market Players
• Nurse Staffing Dominance
• Healthcare Spending by Country

4. Global Antibiotic Resistance Market, By Drug Class, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Oxazolidinones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Lipoglycopeptides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Tetracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Cephalosporins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Combination therapies, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Antibiotic Resistance Market, By Disease, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• cUTI (Complicated Urinary Tract Infections)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• CDI (Clostridioides difficile Infection)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• ABSSSI (Acute bacterial skin and skin structure infections)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• HABP (Hospital-acquired bacterial pneumonia)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• CABP (Community-acquired pneumonia)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• cIAI (Complicated intra-abdominal infection)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (BSI (Bloodstream infection), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Antibiotic Resistance Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Antibiotic Resistance Market, By Region, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profile
  • Melinta Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Allergan
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Tetraphase Pharmaceutical, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • TeamHealth
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Theravance Biopharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • WOCKHARDT
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Entasis Threapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Paratek Pharmaceutials, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Seres Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Achaogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Basilea Pharmaceutical Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Nabriva Threapeutics plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • NEMESIS BIOSCIENCE LTD.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About us